A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

被引:116
|
作者
Charpentier, B [1 ]
Rostaing, L
Berthoux, F
Lang, P
Civati, G
Touraine, JL
Squifflet, JP
Vialtel, P
Abramowicz, D
Mourad, G
Wolf, P
Cassuto, E
Moulin, B
Rifle, G
Pruna, A
Merville, P
Mignon, F
Legendre, C
Le Pogamp, P
Lebranchu, Y
Toupance, O
de Ligny, BH
Touchard, G
Olmer, M
Purgus, R
Pouteil-Noble, C
Glotz, D
Bourbigot, B
Leski, M
Wauters, JP
Kessler, M
机构
[1] Hop Bicetre, Serv Nephrol, Le Kremlin Bicetre, France
[2] CHU Toulouse, Hop Rangueil, Unite Transplantat Organes, Toulouse, France
[3] Hop Nord St Etienne, Serv Nephrol & Transplantat, St Etienne, France
[4] Hop Henri Mondor, Serv Nephrol, F-94010 Creteil, France
[5] Azienda Osped Osped Niguarda Ca Granda, Div Nefrol & Dialisi, Milan, Italy
[6] Hop Edouard Herriot, Serv Transplantat & Immunol Clin, Lyon, France
[7] Clin Univ St Luc, Serv Transplantat Renale & Chirurg Glandes Endocr, B-1200 Brussels, Belgium
[8] CHU Nord, Hop Michallon, Serv Nephrol & Transplanatat, Grenoble, France
[9] Clin Univ Hop Erasme, Dept Nephrol, Brussels, Belgium
[10] Hop Lapeyronie, Serv Chirurg Gen & Transplantat, F-34059 Montpellier, France
[11] Hop Hautepierre, Serv Chirurg Gen & Transplantat Multiorganes, Strasbourg, France
[12] Hop Louis Pasteur, Serv Nephrol, Nice, France
[13] Hop Civil, Serv Nephrol & Hemodialyse, Strasbourg, France
[14] Hop Bocage, Serv Nephrol & Reanimat Metab, Dijon, France
[15] CHU Amiens, Hop Sud, Serv Nephrol, Amiens, France
[16] Hop Pellegrin, Serv Nephrol, F-33076 Bordeaux, France
[17] Hop Bichat Claude Bernard, Serv Nephrol, Paris, France
[18] Hop St Louis, Serv Nephrol, Paris, France
[19] CHU Pontchaillou, Serv Nephrol, Rennes, France
[20] Hop Bretonneau, Serv Nephrol, Tours, France
[21] Hop Maison Blanche, Serv Nephrol, Reims, France
[22] Hop Clemenceau, Serv Nephrol & Hemodialyse, Caen, France
[23] Cite Hosp Miletrie, Poitiers, France
[24] Hop Conception, Serv Nephrol & Hemodialyse, Marseille, France
[25] Ctr Hosp Lyon Sud, Serv Nephrol, F-69310 Pierre Benite, France
[26] Hop Georges Pompidou, Serv Nephrol, Paris, France
[27] Hop Cavale Blanche, Serv Nephrol, Brest, France
[28] Univ Geneva, Hop Cantonal, Div Nephrol, Dept Med, CH-1211 Geneva, Switzerland
[29] CHU Vaudois, Div Nephrol, Dept Med, CH-1011 Lausanne, Switzerland
[30] CHU Nancy, Hop Brabois, Serv Nephrol & Transplantat, Vandoeuvre Les Nancy, France
关键词
D O I
10.1097/01.TP.0000056635.59888.EF
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Induction therapy with antithymocyte globulin (ATG) reduces the incidence of acute rejection after transplantation. A study was undertaken to assess the efficacy and safety of ATG induction on tacrolimus-based and cyclosporine A (CsA)-based therapies compared with immediate tacrolimus triple therapy in kidney transplant recipients. Methods. In a 6-month, open-label, randomized, prospective study conducted in 30 European centers, 555 renal transplant patients were randomly assigned to tacrolimus triple therapy (Tac triple, n=185), ATG induction with tacrolimus (ATG-Tac, n= 186), or ATG induction with CsA microemulsion (ATG-CsA, n=184); all were combined with azathioprine, and corticosteroids. The primary endpoint was incidence and time to first acute rejection episode confirmed by biopsy. Results. Patient demographics and clinical parameters at baseline were similar. Patient and graft survival rates were similar in all groups. The incidence of clinically apparent acute rejection was significantly higher (P=0.003) for Tac triple (33.0%) compared with ATG-Tac (22.6%) and the incidence for ATG-Tac was significantly lower (P=0.004) than for ATG-CsA (37.0%). The incidences of acute rejection confirmed by biopsy (primary endpoint) were 25.4%, 15.1%, and 21.2% for Tac triple, ATG-Tac, and ATG-CsA, respectively (Tac triple vs. ATG-Tac, P=0.004). The incidences of corticosteroid-resistant acute rejection were 7.0% (Tac triple), 4.8% (ATG-Tac), and 10.9% (ATG-CsA) (ATG-Tac vs. ATG-CsA, P=0.038). In the ATG groups, the incidences of leukopenia, thrombocytopenia, serum sickness, fever, and cytomegalovirus infection were significantly higher (P<0.05). Conclusions. Acute rejection was significantly lower in the ATG-Tac group compared with the ATG-CsA and Tac triple groups. Significantly more hematologic and infectious adverse events were observed in both ATG induction groups.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 50 条
  • [1] A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients
    Charpentier, B
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1625 - 1626
  • [2] Conversion from cyclosporine to tacrolimus based immunosuppression therapy in renal transplant recipients
    Backman, Lars
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (04) : A33 - A33
  • [3] Cyclosporine Versus Tacrolimus Maintenance Therapy in Renal Transplant
    Alghamdi, Saad
    Nabi, Zahid
    Skolnik, Edward
    Alkorbi, Lutfi
    Albaqumi, Mamdouh
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2011, 9 (03) : 170 - 174
  • [4] A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients
    Goring, Sarah M.
    Levy, Adrian R.
    Ghement, Isabella
    Kalsekar, Anupama
    Eyawo, Oghenowede
    L'Italien, Gilbert J.
    Kasiske, Bertram
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1473 - 1487
  • [5] Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy
    Chisholm, MA
    Mulloy, LL
    DiPiro, JT
    CLINICAL TRANSPLANTATION, 2005, 19 (01) : 77 - 82
  • [6] Comparison of Renal Outcomes for Liver Transplant Recipients With Pretransplant Renal Dysfunction Receiving Sirolimus Or Tacrolimus With Rabbit Antithymocyte Globulin Induction
    Duhart, B.
    Ally, W.
    Rao, V.
    Krauss, A.
    Eason, J.
    Vanatta, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [7] Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients
    Ogino, S
    Hashikura, Y
    Katsuyama, Y
    Ikegami, T
    Nakazawa, Y
    Urata, K
    Terada, M
    Miyagawa, S
    Kawasaki, S
    TRANSPLANTATION PROCEEDINGS, 2004, 36 (02) : 299S - 301S
  • [8] Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunusuppressant therapy.
    Chisholm, MA
    McGinty, HE
    Mulloy, LL
    PHARMACOTHERAPY, 2004, 24 (10): : 1468 - 1468
  • [9] A Randomized, Single-Center Trial Comparing Thymoglobulin (TG) Induction Therapy and Delayed Initiation of Tacrolimus to No Induction with Immediate Initiation of Tacrolimus in Liver Transplant (LT) Recipients To Assess the Impact on Renal Function
    Grant, W.
    Botha, J.
    Mercer, D.
    Olivera-Martinez, M.
    McCashland, T.
    Langnas, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 539 - 539
  • [10] A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients
    Kasiske, BL
    Johnson, HJ
    Goerdt, PJ
    HeimDuthoy, KL
    Rao, VK
    Dahl, DC
    Ney, AL
    Andersen, RC
    Jacobs, DM
    Odland, MD
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (05) : 639 - 645